Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
The war is changing the situation on the drug market: there is a certain shortage with imported medicines, and many of the Western pharmaceutical companies are still operating in the…